Translational Development Acquisition (TDACW) EPS (Basic) (2024 - 2026)

Translational Development Acquisition (TDACW) has reported EPS (Basic) for 3 consecutive years, with $0.03 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EPS (Basic) fell 40.88% year-over-year to $0.03; the trailing twelve-month figure through Jun 2026 stood at $0.2 (up 86.23% YoY), and the FY2025 full-year result was $0.29, up 1896.41% from the prior year.
• EPS (Basic) retreated to $0.03 in Q2 2026 per TDACW's latest filing, from $0.05 in the prior quarter.
• Across five years, EPS (Basic) topped out at $0.07 in Q4 2025 and bottomed at -$0.02 in Q3 2024.
• Historically, EPS (Basic) has averaged $0.04 across 3 years, with a median of $0.05 in 2026.
• The sharpest annual moves came in 2025 and 2026: EPS (Basic) surged 11074.69% in 2025, then sank 40.88% in 2026.
• Over 3 years, EPS (Basic) stood at -$0.0 in 2024, then surged by 11074.69% to $0.07 in 2025, then plunged by 52.65% to $0.03 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $0.03, $0.05, and $0.07 for Q2 2026, Q1 2026, and Q4 2025 respectively.